Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Ascendis Pharma A/S (“Ascendis” or the “Company”) (NASDAQ: ASND) on behalf of Ascendis stockholders. Our investigation concerns whether Ascendis has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On April 3, 2023, Ascendis issued a press release "announc[ing] that the U.S. Food & Drug Administration (FDA) has notified the Company that, as part of their ongoing review, the FDA has identified deficiencies in the Company's New Drug Application (NDA) for TransCon PTH (palopegteriparatide) in hypoparathyroidism that at this time precludes them from holding further discussions about labeling and post-marketing requirements/commitments. The deficiencies were not disclosed in the letter."
On this news, Ascendis's American depositary receipt ("ADR") price fell $34.39 per ADR, or 32.07%, to close at $72.83 per ADR on April 3, 2023.
If you purchased or otherwise acquired Ascendis shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at firstname.lastname@example.org, by telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.